Potential Anti-Inflammatory Effect of Escitalopram in Iodoacetamide-Induced Colitis in Depressed Ovariectomized Rats: Role of α7-nAChR
- 82 Downloads
Escitalopram, a drug of choice in the treatment of depression, was recently shown to possess an anti-inflammatory activity. The aim of the present study was to elucidate the effect of escitalopram on peripheral inflammatory cascades in iodoacetamide-induced colitis associated with depressive behavior in ovariectomized rats. Moreover, the role of α-7 nicotinic acetylcholine receptor in mediating the anti-colitic effect of escitalopram was examined using a nicotinic receptor antagonist methyllycaconitine citrate. Colitis was induced by intracolonic injection of 4% iodoacetamide in ovariectomized rats. Escitalopram (10 mg/kg/day, i.p.) was then injected for 1 week and several parameters including macroscopic (colon mass index and ulcerative area), microscopic (histopathology and scoring), and biochemical (myeloperoxidase and tumor necrosis factor-α) were determined. Colitis induction in ovariectomized rats resulted in a marked increase in colon mass index, ulcerative area, histopathological scoring, myeloperoxidase activity and tumor necrosis factor-α levels. These effects were ameliorated by escitalopram, even in the presence of methyllycaconitine indicating that α-7 nicotinic acetylcholine receptor does not mediate the anti-inflammatory effect of escitalopram. The present study revealed the beneficial effect of escitalopram in iodoacetamide induced colitis in ovariectomized rats and suggests that it may represent a new therapeutic agent for the treatment of inflammatory bowel disease, especially in patients with or at high risk of depressive behavior.
KEY WORDSEscitalopram colitis depression α7-nAChR iodoacetamide ovariectomy methyllycaconitine
The authors are grateful to Prof. Laila A. Rashed (Medical Biochemistry Department, Faculty of Medicine, Cairo University, Egypt), for her valuable assistance in ELIZA and Western blotting procedures. The authors are also thankful to Prof. Nermeen Shaffie (Department of Pathology, National Research Centre, Cairo, Egypt) for her precious efforts in histological examinations.
All authors contribute equally.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that there is no conflict of interests regarding the publication of this paper.
- 7.Dong, C., J.C. Zhang, W. Yao, Q. Ren, C. Yang, M. Ma, M. Han, R. Saito, and K. Hashimoto. 2016. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacology Biochemistry and Behavior 144: 7–12.CrossRefGoogle Scholar
- 11.Grandi, A., I. Zini, L. Flammini, A.M. Cantoni, V. Vivo, V. Ballabeni, E. Barocelli, and S. Bertoni. 2017. alpha7 nicotinic agonist AR-R17779 protects mice against 2,4,6-Trinitrobenzene sulfonic acid-induced colitis in a spleen-dependent way. Frontiers in Pharmacology 8: 809.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Polverini, P. 1997. Role of the macrophage in angiogenesis-dependent diseases, in Regulation of angiogenesis, 11–28. Berlin: Springer.Google Scholar
- 27.Mittermaier, C., C. Dejaco, T. Waldhoer, A. Oefferlbauer-Ernst, W. Miehsler, M. Beier, W. Tillinger, A. Gangl, and G. Moser. 2004. Impact of depressive mood on relapse in patients with inflammatory bowel disease: A prospective 18-month follow-up study. Psychosomatic Medicine 66 (1): 79–84.CrossRefPubMedGoogle Scholar
- 29.Bah, T.M., M. Benderdour, S. Kaloustian, R. Karam, G. Rousseau, and R. Godbout. 2011. Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behavioural Brain Research 225 (1): 243–251.CrossRefPubMedGoogle Scholar